var data={"title":"Amino acids solutions for parenteral nutrition: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amino acids solutions for parenteral nutrition: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7466?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amino-acids-solutions-for-parenteral-nutrition-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amino acids solutions for parenteral nutrition: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6798101\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aminosyn;</li>\n      <li>Aminosyn II;</li>\n      <li>Aminosyn II/Electrolytes;</li>\n      <li>Aminosyn M;</li>\n      <li>Aminosyn-HBC;</li>\n      <li>Aminosyn-HF [DSC];</li>\n      <li>Aminosyn-PF;</li>\n      <li>Aminosyn-RF;</li>\n      <li>Aminosyn/Electrolytes;</li>\n      <li>Clinimix E/Dextrose (2.75/10);</li>\n      <li>Clinimix E/Dextrose (2.75/5);</li>\n      <li>Clinimix E/Dextrose (4.25/10);</li>\n      <li>Clinimix E/Dextrose (4.25/25);</li>\n      <li>Clinimix E/Dextrose (4.25/5);</li>\n      <li>Clinimix E/Dextrose (5/15);</li>\n      <li>Clinimix E/Dextrose (5/20);</li>\n      <li>Clinimix E/Dextrose (5/25);</li>\n      <li>Clinimix N14G30E;</li>\n      <li>Clinimix N9G15E;</li>\n      <li>Clinimix N9G20E;</li>\n      <li>Clinimix/Dextrose (2.75/5);</li>\n      <li>Clinimix/Dextrose (4.25/10);</li>\n      <li>Clinimix/Dextrose (4.25/20);</li>\n      <li>Clinimix/Dextrose (4.25/25);</li>\n      <li>Clinimix/Dextrose (4.25/5);</li>\n      <li>Clinimix/Dextrose (5/15);</li>\n      <li>Clinimix/Dextrose (5/20);</li>\n      <li>Clinimix/Dextrose (5/25);</li>\n      <li>Clinisol SF;</li>\n      <li>FreAmine HBC;</li>\n      <li>FreAmine III;</li>\n      <li>Hepatamine;</li>\n      <li>NephrAmine;</li>\n      <li>Plenamine;</li>\n      <li>Premasol;</li>\n      <li>Prosol;</li>\n      <li>Synthamin 17;</li>\n      <li>Travasol;</li>\n      <li>TrophAmine;</li>\n      <li>Trophamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934087\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aminosyn;</li>\n      <li>Aminosyn II;</li>\n      <li>Aminosyn-RF;</li>\n      <li>Clinimix;</li>\n      <li>Clinimix E;</li>\n      <li>Primene</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6798102\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Intravenous Nutritional Therapy</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6798111\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Correct severe fluid, electrolyte, and acid-base disorders prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Component of parenteral nutrition: </b> Protein as amino acids: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Maintenance:</b> 0.8 to 1 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Normal/mild stress level:</b> 1 to 1.2 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderate stress level:</b> 1.2 to 1.5 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe stress level:</b> 1.5 to 2 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Burn patients (severe):</b> Increase protein until significant wound healing achieved</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Solid organ transplant:</b> Perioperative: 1.5 to 2 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal failure:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute (severely malnourished or hypercatabolic): 1.5 to 1.8 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic, with dialysis: 1.2 to 1.8 g/kg/day (maximum: 2.5 g/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic, without dialysis: 0.6 to 0.8 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CRRT: 1.2 to 1.8 g/kg/day (maximum: 2.5 g/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic failure:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute management when other treatments have failed:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">With encephalopathy: 0.6 to 1 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Without encephalopathy: 1 to 1.5 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic encephalopathy: Use branch chain amino acid enriched diets only if unresponsive to pharmacotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pregnant women in second or third trimester:</b> Add an additional 10 to 14 g/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6798110\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Component of parenteral nutrition: </b> Protein as amino acids: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Term:</b> Initial: 2.5 g/kg/day; Goal: 3 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extremely (&lt;1,000 g) and very (&lt;1,500 g) low-birth-weight (stable):</b> Initial: 1 to 1.5 g/kg/day; Goal: 3.5 to 3.85 g/kg/day to promote utero growth rates</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sepsis, hypoxia:</b> Initial: 1 g/kg/day; goal: 3 to 3.85 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Clinimix, Clinimix E, Travasol: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;1 month of age: 3 to 4 g /kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 month to &lt;1 year: 2 to 3 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;11 years: 1 to 2 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;11 years and Adolescents &le;17 years: 0.8 to 1.5 g/kg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671603\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671604\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238292\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn: 3.5% (1000 mL [DSC]); 7% (500 mL [DSC]); 8.5% (500 mL, 1000 mL [DSC]); 10% (500 mL, 1000 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn II: 10% (2000 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn II: 15% (2000 mL [DSC]) [latex free; contains sodium hydrosulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn II: 7% (500 mL [DSC]); 8.5% (500 mL, 1000 mL [DSC]); 10% (2000 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn II: 10% (500 mL, 1000 mL); 15% (2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn II/Electrolytes: 8.5% (500 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn M: 3.5% (1000 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn-HBC: 7% (500 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn-HF: 8% (500 mL [DSC]) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn-PF: 7% (500 mL); 10% (1000 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn-RF: 5.2% (500 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aminosyn/Electrolytes: 8.5% (500 mL, 1000 mL) [latex free, sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (2.75/10): 2.75% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (2.75/5): 2.75% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (4.25/10): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (4.25/25): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (4.25/5): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (5/15): 5% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (5/20): 5% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix E/Dextrose (5/25): 5% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix N14G30E: 4.25% (2000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix N9G15E: 2.75% (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix N9G20E: 2.75% (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (2.75/5): 2.75% (1000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (4.25/10): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (4.25/20): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (4.25/25): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (4.25/5): 4.25% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (5/15): 5% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (5/20): 5% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinimix/Dextrose (5/25): 5% (1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clinisol SF: 15% (500 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FreAmine HBC: 6.9% (750 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FreAmine III: 10% (1000 mL) [contains sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatamine: 8% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NephrAmine: 5.4% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plenamine: 15% (1000 mL) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premasol: 6% (500 mL); 10% (500 mL, 1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prosol: 20% (2000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthamin 17: 10% (3000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Travasol: 10% (500 mL, 1000 mL, 2000 mL) [sulfite free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trophamine: 6% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TrophAmine: 10% (500 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452401\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238295\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administered as a component of peripheral parenteral or total parenteral nutrition. Central or peripheral administration of nutrition is dependent upon osmolality of solution. Solutions with &gt;5% dextrose or osmolarity &ge;900 mOsm/L must be infused via central venous catheter. Total parenteral nutrition must be administered via central venous access. May require use of inline filter (consult specific product labeling and/or individual institutional policies and procedures). Initiation and termination of nutritional fluids must be gradual to permit endogenous insulin release adjustment. Consult specific product labeling for maximum infusion rates.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238294\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Component of parenteral nutrition:</b> As part of parenteral nutrition to prevent nitrogen loss or treat negative nitrogen balance when alimentary tract cannot be used (eg, GI absorption is impaired, bowel rest is needed). Specialty amino acid formulas may be considered only in certain instances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7913784\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">TrophAmine may be confused with tromethamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238285\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Phlebitis, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Fluid and electrolyte disturbance </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Azotemia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238297\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to one or more amino acids, dextrose, or any component of the formulation; inborn errors of amino acid metabolism; hepatic coma, severe renal failure, metabolic disorders involving impaired nitrogen utilization (excluding Clinimix, Clinimix E, and Travasol); pulmonary edema or acidosis due to low cardiac output (Clinimix, Clinimix E, and Travasol); neonates (&lt;28 days of age) receiving concomitant ceftriaxone (Clinimix E).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): <b>Note:</b> Contraindications vary per manufacturer labeling (refer also to specific product labeling): Anuria (untreated); acute renal failure and without undergoing renal replacement therapy; severe liver failure; severe hyperglycemia (ie, glucose &ge;180 mg/dL); simultaneous administration of ceftriaxone through the same infusion line in patients &gt;28 days of age; hypernatremia; hyperkalemia; hypercalcemia; hyperphosphatemia; hypermagnesemia; coadministration with calcium-containing intravenous solutions; azotemia from any cause (if not accounting for total nitrogen intake)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238283\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Parenteral nutrition associated liver disease has been reported in patients receiving parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis; cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, and hepatic failure have also been reported. Increase in blood ammonia levels and hyperammonemia may also occur. Consider discontinuation or dose reduction in patients who develop abnormal LFTs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia or hyperosmolar hyperglycemic state: Administration of dextrose at a rate exceeding the patient&rsquo;s utilization rate may lead to hyperglycemia, coma, and death. Patients with underlying confusion and renal impairment who receive dextrose infusions may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/infusion reactions: Hypersensitivity/infusion reactions including anaphylaxis have been reported. Stop infusion immediately and treat patient accordingly if any signs or symptoms of a hypersensitivity reaction develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Refeeding syndrome: Refeeding severely undernourished patients may result in refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase nutrient intakes, while avoiding overfeeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, cardiac insufficiency due to left ventricular systolic dysfunction, heart failure); these patients are susceptible to excessive fluid accumulation; dosage adjustments may be necessary. Consider concentrated total parenteral nutrition formula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus. Monitor blood glucose levels and treat hyperglycemia to maintain optimum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Consider volume status in patients with hepatic failure, may require concentrated total parenteral nutrition formula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disorders: Use with caution in patients with pulmonary congestion; these patients are susceptible to excessive fluid accumulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may be at risk of electrolyte and fluid volume imbalance; dosage adjustments may be necessary. May contain aluminum, which may accumulate following prolonged administration in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ceftriaxone: Precipitation of ceftriaxone-calcium may occur when ceftriaxone is mixed with calcium-containing parenteral nutrition solutions in the same IV line. Do not administer ceftriaxone simultaneously via a Y-site with calcium-containing parenteral solutions. Concurrent use is contraindicated in neonates &lt;28 days receiving ceftriaxone. In patients &ge;28 days, may administer sequentially if the infusion lines are thoroughly flushed between infusions with a compatible fluid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Precipitates: Periodically inspect solution, infusion set and catheter for precipitates. Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress has been reported (some fatal). If signs of pulmonary distress occur, stop the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some products may contain sulfites as preservatives.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warning/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For central or peripheral IV administration; peripheral administration of nutrition is dependent upon osmolality of solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238289\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334400\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Following administration, an increase of some amino acids is observed in the fetus (Ronzoni 1999; Ronzoni 2002). In women with nausea and vomiting of pregnancy, parenteral nutrition should be used as a last option for any woman who cannot maintain her weight because of vomiting; enteral nutrition is preferred (ACOG 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334401\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous amino acids are present in breast milk (IOM 1991). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238290\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fluid and electrolyte status, serum osmolarity, blood glucose, renal and hepatic function, ammonia levels, blood count and coagulation parameters throughout treatment; serum lipids in patients maintained on fat-free parenteral nutrition; signs and symptoms of infection and frequent checks of the parenteral access device and insertion site for edema, redness and discharge; bone densitometry (upon initiation of long-term therapy); signs/symptoms of hypersensitivity reaction; vitamin A status (in patients with chronic renal failure). Monitor infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29120361\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promote protein synthesis and wound healing, and reduce the rate of endogenous protein catabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322824\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn II Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.5% (500 mL): $15.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1000 mL): $24.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15% (2000 mL): $50.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn II/Electrolytes Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.5% (500 mL): $13.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.5% (500 mL): $10.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1000 mL): $23.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn M Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5% (1000 mL): $12.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn-HBC Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7% (500 mL): $73.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn-PF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7% (500 mL): $44.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1000 mL): $80.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn-RF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5.2% (500 mL): $27.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminosyn/Electrolytes Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.5% (500 mL): $15.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (2.75/10) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.75% (1000 mL): $46.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (2.75/5) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.75% (1000 mL): $46.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (4.25/10) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $49.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (4.25/25) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $51.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (4.25/5) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $45.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (5/15) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $47.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (5/20) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $47.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix E/Dextrose (5/25) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $49.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix N14G30E Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (2000 mL): $91.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix N9G15E Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.75% (1000 mL): $47.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix N9G20E Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.75% (1000 mL): $47.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (2.75/5) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.75% (1000 mL): $41.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (4.25/10) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $40.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (4.25/20) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $42.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (4.25/25) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $40.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (4.25/5) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.25% (1000 mL): $39.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (5/15) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $46.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (5/20) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $47.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinimix/Dextrose (5/25) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $47.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clinisol SF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15% (500 mL): $104.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FreAmine HBC Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.9% (750 mL): $76.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FreAmine III Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1000 mL): $18.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hepatamine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8% (500 mL): $101.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NephrAmine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5.4% (250 mL): $23.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Plenamine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15% (1000 mL): $32.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Premasol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6% (500 mL): $47.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1000 mL): $105.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prosol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (2000 mL): $139.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Synthamin 17 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (3000 mL): $59.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Travasol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1000 mL): $32.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Trophamine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6% (500 mL): $27.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (TrophAmine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (500 mL): $28.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059465\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amino-Steril K (EG);</li>\n      <li>Amino-Steril N-Hepa (EG);</li>\n      <li>Aminofusin L (SA);</li>\n      <li>Aminolaben (ID);</li>\n      <li>Aminoleban (HK, JP, PH, TH);</li>\n      <li>Aminoplasmal (AE, AR, AT, BE, BG, CL, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IL, IN, IT, LB, LK, LT, LU, NL, PE, PL, PT, QA, RO, RU, SA, SG, SI, SK, TH, TR, UA, VN);</li>\n      <li>Aminoplasmal 10% (MY, TW);</li>\n      <li>Aminoplasmal 5% (MY, TW);</li>\n      <li>Aminoplasmal E (EC);</li>\n      <li>Aminoplasmal Hepa (IN, VN);</li>\n      <li>Aminoplex (BD);</li>\n      <li>Aminosol (BD);</li>\n      <li>Aminosteril (AE, AR, AT, ES, GB, GR, HU, ID, PL, PY, RU, SA, SG, TR, UA, ZA);</li>\n      <li>Aminosteril Hepa (PT);</li>\n      <li>Aminosteril N- Hepa (HR);</li>\n      <li>Aminosteril N-Hepa (BG, CZ, EE, KR, LT, MX, RO, SI, SK);</li>\n      <li>Aminosterol (DE);</li>\n      <li>Aminosyn (PY, UY);</li>\n      <li>Aminoven (AE, CL, DK, HU, LB, LK, QA, RO, UY);</li>\n      <li>Celemin (AE, LK, QA);</li>\n      <li>Eloamin 10% (AT);</li>\n      <li>Eloamin 7% (AT);</li>\n      <li>Freamine (KR);</li>\n      <li>FreAmine (VE);</li>\n      <li>Freamine HBC (ES);</li>\n      <li>FreAmine HBC (VE);</li>\n      <li>FreAmine III (IT, QA);</li>\n      <li>Freamine III (PT, SA);</li>\n      <li>Primene (AU);</li>\n      <li>Repotyn (BD);</li>\n      <li>Synthamin 10% with Electrolytes (NZ);</li>\n      <li>Synthamin 5.5% with Electrolytes (NZ);</li>\n      <li>Synthamin 8% with Electrolytes (NZ);</li>\n      <li>Travasol (QA, SA);</li>\n      <li>Trophamine (ES, MX, SG, TR, VE);</li>\n      <li>Vamin (AU, CN, CY, DE, DK, GB, HK, IL, LU, MT, MX, NL, NO, PL, PT, PY, QA, SA, SE, SI, ZA);</li>\n      <li>Vamin 14 (MY);</li>\n      <li>Vamin N (EG);</li>\n      <li>Vaminolac (NO);</li>\n      <li>Vaminolact (EE, HK, LK, LT, LU, PY, SG, SI, TH, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amino-acids-solutions-for-parenteral-nutrition-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aminosyn (amino acids for injection) [product monograph]. St-Laurent, Quebec, Canada: Hospira Healthcare Corporation; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aminosyn II (amino acids for injection) [product monograph]. St-Laurent, Quebec, Canada: Hospira Healthcare Corporation; June 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clinimix (amino acids in dextrose) [prescribing information]. Deerfield, IL: Baxter Healthcare; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clinimix E (amino acids with electrolytes in dextrose with calcium) [prescribing information]. Deerfield, IL: Baxter Healthcare; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amino-acids-solutions-for-parenteral-nutrition-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM), Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board, National Academy of Sciences, &quot;Nutrition During Lactation,&quot; 1991. Available at <a href=\"http://www.nap.edu/catalog.php?record_id=1577\" target=\"_blank\">http://www.nap.edu/catalog.php?record_id=1577</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amino-acids-solutions-for-parenteral-nutrition-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plenamine 15% (amino acids injection) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amino-acids-solutions-for-parenteral-nutrition-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ronzoni S, Marconi AM, Cetin I, et al, &quot;Umbilical Amino Acid Uptake at Increasing Maternal Amino Acid Concentrations: Effect of a Maternal Amino Acid Infusate,&quot; <i>Am J Obstet Gynecol</i>, 1999, 181(2):477-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amino-acids-solutions-for-parenteral-nutrition-drug-information/abstract-text/10454703/pubmed\" target=\"_blank\" id=\"10454703\">10454703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ronzoni S, Marconi AM, Paolini CL, et al, &quot;The Effect of a Maternal Infusion of Amino Acids on Umbilical Uptake in Pregnancies Complicated by Intrauterine Growth Restriction,&quot;<i> Am J Obstet Gynecol</i>, 2002, 187(3):741-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amino-acids-solutions-for-parenteral-nutrition-drug-information/abstract-text/12237657/pubmed\" target=\"_blank\" id=\"12237657\">12237657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Travasol (amino acids injection) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9355 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6798101\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2934087\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6798102\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6798111\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6798110\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671603\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671604\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F238292\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452401\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F238295\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F238294\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7913784\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F238285\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F238297\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F238283\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F238289\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13334400\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13334401\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F238290\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F29120361\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322824\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059465\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9355|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amino-acids-solutions-for-parenteral-nutrition-patient-drug-information\" class=\"drug drug_patient\">Amino acids solutions for parenteral nutrition: Patient drug information</a></li></ul></div></div>","javascript":null}